Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms  Janine Prick, Gerald de Haan, Anthony R. Green,

Slides:



Advertisements
Similar presentations
GENETICS & biology OF MYELOPROLIFERATIVE NEOPLASMS
Advertisements

Myeloid Blastic Transformation of Myeloproliferative Neoplasms A Review of 112 Cases Presenter: Syed Jawad Noor, PGY3 Mentor: Meir Wetzler June 09, 2010.
Myeloproliferative Disorders (MPDs)
Complete Hematological Molecular and Histological Remissions without Cytoreductive Treatment Lasting After Pegylated-Interferon -2a (peg-IFN-2a) Therapy.
Functional Analysis of the Neurofibromatosis Type 2 Protein by Means of Disease- Causing Point Mutations Renee P. Stokowski, David R. Cox The American.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Myeloproliferative Neoplasms: A Contemporary Review.
Oxidative stress and hypoxia in normal and leukemic stem cells Ugo Testa, Catherine Labbaye, Germana Castelli, Elvira Pelosi Experimental Hematology Volume.
Christina A. Ortmann, M.D., David G. Kent, Ph.D., Jyoti Nangalia, M.B.Chir., F.R.C.Path., Yvonne Silber, M.Sc.,David C. Wedge, Ph.D., Jacob Grinfeld, M.B.
Fabian Mohr, Konstanze Döhner, Christian Buske, Vijay P.S. Rawat 
Diagnostic algorithm for suspected essential thrombocythemia
Age-associated changes in human hematopoietic stem cells
Susanne Wingert, Michael A. Rieger  Experimental Hematology 
by David P. Steensma, Rafael Bejar, Siddhartha Jaiswal, R
Chronic Myeloproliferative Neoplasms (MPN) Ph-negative
Volume 14, Issue 6, Pages (June 2014)
Ling Guo, Robert C.H. Zhao, Yaojiong Wu  Experimental Hematology 
Nishitha M. Reddy, Olalekan Oluwole, John P. Greer, Brian G
The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity by Chloe James, Frederic.
V617F “JAKs” up myeloproliferative signal
Cassie J. Clarke, Tessa L. Holyoake  Experimental Hematology 
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report.
Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer
Ayalew Tefferi, MD, Tiziano Barbui, MD  Mayo Clinic Proceedings 
Detection of CALR and MPL Mutations in Low Allelic Burden JAK2 V617F Essential Thrombocythemia  Fabrice Usseglio, Nathalie Beaufils, Anne Calleja, Sophie.
Clonal analysis of thymus-repopulating cells presents direct evidence for self-renewal division of human hematopoietic stem cells by Takashi Yahata, Shizu.
by R. Coleman Lindsley, and Benjamin L. Ebert
GATA2 finds its macrophage niche
Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications  Mahmoud I. Elbadry,
Sca-1 is an early-response target of histone deacetylase inhibitors and marks hematopoietic cells with enhanced function  Marta A. Walasek, Leonid V.
Kinetics and symmetry of divisions of hematopoietic stem cells
CBP/Catenin antagonists: Targeting LSCs’ Achilles heel
Getting blood from bone: An emerging understanding of the role that osteoblasts play in regulating hematopoietic stem cells within their niche  Yusuke.
Ashok Kumar Jayavelu, Jennifer N. Moloney, Frank-D. Böhmer, Thomas G
Quiescence regulators for hematopoietic stem cell
Reiner Schulte, Nicola K. Wilson, Janine C. M
A Real-Time Polymerase Chain Reaction Assay for Rapid, Sensitive, and Specific Quantification of the JAK2V617F Mutation Using a Locked Nucleic Acid-Modified.
Oceans of opportunity: Exploring vertebrate hematopoiesis in zebrafish
Induced pluripotent stem cell modeling of malignant hematopoiesis
Christopher E. Schmitt, Carlos O. Lizama, Ann C. Zovein 
Arterial identity of hemogenic endothelium: a key to unlock definitive hematopoietic commitment in human pluripotent stem cell cultures  Igor I. Slukvin,
Pathogenesis of myeloproliferative neoplasms
Susanne Wingert, Michael A. Rieger  Experimental Hematology 
Adam P. Deveau, Victoria L. Bentley, Jason N. Berman 
A dual role of Erk signaling in embryonic stem cells
Experimental Hematology
Ayalew Tefferi, Pierre Noel, Curtis A. Hanson 
Stem Cells and Cancer: Two Faces of Eve
Aging-Induced Stem Cell Mutations as Drivers for Disease and Cancer
Peter Karagiannis, Shinya Yamanaka, Megumu K. Saito 
Volume 6, Issue 3, Pages (March 2010)
Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies  Francesca L. Nice,
Optimizing autologous cell grafts to improve stem cell gene therapy
Inside This Issue Experimental Hematology
Sietske T. Bakker, Emmanuelle Passegué  Experimental Hematology 
Fabian Mohr, Konstanze Döhner, Christian Buske, Vijay P.S. Rawat 
Geneviève Despars, Helen C O'Neill  Experimental Hematology 
Kinase signaling and targeted therapy for primary myelofibrosis
Erratum Experimental Hematology
Sanger sequencing results
Stem cell biology and the plasticity polemic
Adam P. Deveau, Victoria L. Bentley, Jason N. Berman 
Simón Méndez-Ferrer, María García-Fernández, Carlos L.F. de Castillejo 
Circulating miRNA panel for prediction of acute graft-versus-host disease in lymphoma patients undergoing matched unrelated hematopoietic stem cell transplantation 
Causes and Consequences of Hematopoietic Stem Cell Heterogeneity
Matthew I. Stein, Jiang Zhu, Stephen G. Emerson 
by Elisa Rumi, and Mario Cazzola
Hariharan Easwaran, Hsing-Chen Tsai, Stephen B. Baylin  Molecular Cell 
Time-dependent survival estimation in post–polycythemia vera myelofibrosis. Time-dependent survival estimation in post–polycythemia vera myelofibrosis.
Biomechanical force may promote tumor progression by establishing an aggressive tumor cell hierarchy. Biomechanical force may promote tumor progression.
Pediatric leukemia: Moving toward more accurate models
Presentation transcript:

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms  Janine Prick, Gerald de Haan, Anthony R. Green, David G. Kent  Experimental Hematology  Volume 42, Issue 10, Pages 841-851 (October 2014) DOI: 10.1016/j.exphem.2014.07.268 Copyright © 2014 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 1 Classification of myeloproliferative neoplasm (MPN) subtypes. It remains unclear why one mutation is associated with three distinct disease entities. Because diagnosis of MPN patients is based on binary decisions on continuous variables (e.g., platelet count) at single time points, patients with borderline values are difficult to classify. Moreover, primary myelofibrosis (MF) may in fact represent the presentation of the accelerated phase of polycythemia vera (PV) or essential thrombocythemia (ET). Decisions are further complicated by additional factors that could alter presentation (e.g., gene dosage, STAT signaling, the role of interferon (IFN)-α, familial predisposition, and host genetic variation). This variability is further illustrated by the diverse phenotypes observed in different mouse models of JAK2V617F. Experimental Hematology 2014 42, 841-851DOI: (10.1016/j.exphem.2014.07.268) Copyright © 2014 ISEH - International Society for Experimental Hematology Terms and Conditions

Figure 2 Clonal evolution in myeloproliferative neoplasms (MPNs). (A) Normal steady state: On average, for every nonmutant hematopoietic stem cell (HSC) that divides, one daughter cell retains HSC potential. Throughout the life of the organism, the number of HSCs remains approximately constant. (B) A JAK2V617F-mutant HSC divides more frequently. Because the V617F mutation does not confer increased HSC self-renewal, the number of HSCS does not increase; however, each HSC will generate more progenitors that will also divide more frequently. Both HSCs and progenitors, therefore, will undergo additional replicative stress. Consequent selection pressure to acquire a clonal advantage causes one of the heterogeneous population of cells to acquire an additional mutation that drives higher survival and/or self-renewal. The cell that acquires this mutation need not be a HSC, but rather could be any number of JAK2V617F-mutant stem/progenitor cells, and the target cell of the second mutation could therefore determine the disease phenotype. Experimental Hematology 2014 42, 841-851DOI: (10.1016/j.exphem.2014.07.268) Copyright © 2014 ISEH - International Society for Experimental Hematology Terms and Conditions